ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2016

Abstract Number: 2822

Serum 25-Hydroxyvitamin D3 Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis

Chi Chiu Mok1, Eric Bro2, Ling Yin Ho3, Ravinder Singh2 and Paul Jannetto4, 1Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 3Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, 4Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic, Rochester, MN

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: Disease Activity, Lupus and Vitamin D

Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To study the relationship between serum 25-hydroxyvitamin D3 levels and flares of systemic lupus erythematosus (SLE) in a longitudinal cohort of Chinese patients.

Methods: Patients who fulfilled ≥4 of the ACR criteria for SLE were recruited from our rheumatology out-patient clinics in November 2011. Blood was taken at 10 AM and was assayed for the serum levels of 25-hydroxyvitamin D3 by liquid chromatography tandem mass spectrometry (LC-MS/MS). Patients were stratified according to the 25-hydroxyvitamin D3 levels; group 1 (<15ng/ml, deficiency); group 2 (15-30ng/ml, insufficiency); and group 3 (>30ng/ml, adequate); and were followed longitudinally every 2-4 months for serial assessment of disease activity (by SELENA-SLEDAI) and the occurrence of mild/moderate or severe SLE flares (by SELENA flare instrument). Comparison was made among these groups in the baseline and mean summated SLEDAI over time (area under the curve), and the annual incidence of mild/moderate and severe flares by the one-way ANOVA test.

Results: 276 SLE patients were studied (94% women; age 41.0±13.8 years; SLE duration 8.7±6.6 years). 25(9.1%) patients had eGFR ≤60ml/min. The proportion of patients with 25-hydroxyvitamin D3 levels of <15, 15-30, >30ng/ml was 26%, 54% and 20%, respectively. Patients with vitamin D deficiency (group 1) were significantly younger, had lower body mass index (BMI) but higher baseline eGFR and SLEDAI scores when compared with the other groups. No significant differences in the clinical manifestations were observed among the three groups of patients except for lower prevalence of facial rash in group 3 (p=0.02). After a mean follow-up of 32.5±5.5 months, 153 mild flares and 91 severe flares developed in our patients. The mean summated SLEDAI score over time was: 3.2±2.0 (group 1); 2.4±1.9 (group 2); and 2.7±2.1 (group 3), respectively (p=0.02). The annual incidence of mild/moderate and severe flares was: 0.26±0.39 and 0.20±0.45 (group 1); 0.20±0.33 and 0.09±0.22 (group 2); and 0.20±0.32 and 0.14±0.46 (group 3), respectively (p=NS in all). In a subgroup of 73 patients who did not have clinical or serological SLE activity at baseline (SLEDAI=0), a similar but non-significant trend of higher annual rates of mild/moderate and severe flares over time was also observed in patients with vitamin D deficiency. At the last visit, 27 (10%) patients had new damage scores; 5 patients had new vascular events; and 4 patients had new onset diabetes mellitus. There were no significant differences among the three groups of patients with regard to the incidence of new damage or vascular events over time.

Conclusion: Vitamin D insufficiency and deficiency was frequent in our cohort of SLE patients. Patients with vitamin D deficiency were associated with higher baseline and mean disease activity scores, as well as a tendency of more severe lupus flares over time.  


Disclosure: C. C. Mok, None; E. Bro, None; L. Y. Ho, None; R. Singh, None; P. Jannetto, None.

To cite this abstract in AMA style:

Mok CC, Bro E, Ho LY, Singh R, Jannetto P. Serum 25-Hydroxyvitamin D3 Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/serum-25-hydroxyvitamin-d3-levels-and-flares-of-systemic-lupus-erythematosus-a-longitudinal-cohort-analysis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-25-hydroxyvitamin-d3-levels-and-flares-of-systemic-lupus-erythematosus-a-longitudinal-cohort-analysis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology